Dr Virag Kushwaha (Eastern Heart Clinic, New South Wales, AU) joins us to discuss 30-day outcomes of valve-in-valve transcatheter aortic valve replacement using the Navitor system in patients with failed surgical aortic bioprosthetic valves.

As the population of patients with ageing surgical bioprostheses continues to grow, valve-in-valve TAVR has become an increasingly important treatment pathway. The Navitor system, with its self-expanding design and intra-annular sealing, offers potential advantages in this anatomically complex setting, where haemodynamic performance and paravalvular leak remain key concerns.

Interview Questions:

1. What are the key challenges of valve-in-valve TAVR compared to native valve intervention?
2. What characteristics of the Navitor system make it well-suited to this indication?
3. What were the headline 30-day outcomes from this analysis?
4. What do these findings suggest about the safety and performance of Navitor in the valve-in-valve setting?
5. What are your take-home messages for operators considering Navitor for failed surgical bioprostheses?

Recorded on-site at EuroPCR 2026, Paris.
Editors: Jordan Rance
Videographer: Dan Brent
Support: This is an independent interview produced by Radcliffe Cardiology.